Clinical Trials Update: Aug. 14, 2008 (HealthDay via Yahoo! News)
(HealthDay News) -- Here are the latest clinical trials, courtesy of CenterWatch:
us.rd.yahoo.com

ISENTRESS(R) (raltegravir), Merck's First in Class Integrase Inhibitor, Reduced HIV Viral Load and Increased CD4 Cell ... (Business Wire via Yahoo! Finance)
WHITEHOUSE STATION, N.J.----ISENTRESS® , Merck & Co., Inc.'s first-in-class integrase inhibitor, in combination with two other anti-HIV medicines, reduced HIV viral load to undetectable levels in 83 percent of previously untreated HIV-infected patients which was comparable to that seen with efavirenz *, which reduced HIV viral load to undetectable levels in 84 percent of treatment-naive ...
us.rd.yahoo.com